Business
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
Boca Raton, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript, titled, “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,” has been submitted for peer review to npj Dementia, a Nature Portfolio journal. The detailed man
About this update from Inmune Bio Inc.
[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ESFQnG17m_59Q1hSBmvAug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Boca Raton, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript, titled, “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,” has been submitted for peer review to npj Dementia, a Nature Portfolio journal.","length":483,"tagName":"p"},{"type":"text","content":"The detailed manuscript provides a comprehensive analysis of the trial, which evaluated the safety and efficacy of XPro™ in patients with early Alzheimer's disease and biological signs of inflammation. While the study did not meet its primary endpoint in the overall population, the findings reveal a promising signal in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden, defined by two or more biomarkers of inflammation, referred to as the ADi population. A pre-print of the article can be found by clicking here or following this link: https://www.medrxiv.org/content/10.1101/2025.09.24.25336496v1","length":664,"tagName":"p"},{"type":"text","content":""The publication of the MINDFuL trial results with the scientific community highlight the potential therapeutic value of our XPro platform. We are encouraged by the trial results of the subgroup analysis, in addition to the demonstrated strong safety profile, which we believe favorably positions XPro™ for clinical trial advancement,” said CJ Barnum, VP of Neuroscience at INmune Bio.","length":390,"tagName":"p"},{"type":"text","content":"Key findings within the biomarker-enriched ADi population include:","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","co...